Sneha Bharadwaj

Dr. Sneha Bharadwaj


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2014 in Australian Health Review
Verified
Journal Article
Open access
PDF file
SBSneha Bharadwaj
Sneha Bharadwaj
DBDavid Bruce
David Bruce
Objectives: Rehabilitation in the home (RITH) services increasingly provide hospital substitution services. This study examines clinical outcomes in a large metropolitan RITH service in Western Australia. Methods: The 2010 database of Fremantle Hospital RITH service was interrogated to identify the clinical profile of cases, length of stay (LOS) and clinical outcomes. Negative outcomes included death or unexpected hospital readmission. Multiple logistic regression modelling was used to explore associations with negative outcomes. This study was reviewed by the Institutional Review Board which deemed it not to require ethics approval. Results: There were 1348 cases managed by RITH: 70.6% were aged = 65 years; elective joint replacement (29.7%), medical conditions (20%), stroke (13%), hip fractures (10%) were major contributors. The majority (93.3%) were discharged after a median of 9 days. Negative outcomes occurred in 90 cases (6.7%), including five deaths (0.4%) and 85 readmissions (6.3%). Independent associations with negative outcomes included older age (odds ratio (OR) (95% CI); 1.02, P = 0.006), orthopaedic conditions (OR 1.91, P = 0.004) and longer inpatient LOS (OR 1.96, P = 0.003). Age above 80 years was independently associated with risk of negative outcome (OR 2.99, P = 0.004). Conclusions: RITH had a low rate of negative outcomes. The database proved useful for monitoring quality of service provision. What is known about the topic?: Rehabilitation in the home environment has proven cost effective for multiple conditions, particularly stroke and elective joint surgery, among others, facilitating better quality of life, with reduced rates of delirium and mortality. Overall there are few negative outcomes and death is rare. What does this paper add?: Although RITH services are widely utilised as bed substitution services, there is scant literature on clinical outcomes while within the service. This study focuses on frequency of good and poor clinical outcomes in a well-established RITH service in Western Australia, suggesting pattern recognition of an at-risk cohort by identifying potentially useful predictors of poor outcome. What are the implications for practitioners?: RITH services are a safe alternative for many, including older people. Health administration databases are useful tools to monitor clinical outcomes. Clinical indicators such as older age, long hospital stay and orthopaedic diagnoses may be useful predictors of poor outcomes in such services.

1 June 2016 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
SBSneha Bharadwaj
Sneha Bharadwaj
AMAndrew Campbell Moffat
Andrew Campbell Moffat
BWBrad Wood
Brad Wood
ABAvinash Bharadwaj
Avinash Bharadwaj
An elderly man presented with severe right ear pain and discharge, hoarseness and dysphagia causing significant involuntary weight loss. Extensive investigations by varied specialties only highlighted right vocal cord palsy and right parotid lymphadenitis. Reassessment on transfer to a rehabilitation ward noted clinically subtle right Ramsay Hunt syndrome with multiple lower cranial nerve involvement. We illustrate a case of varicella zoster virus cranial polyneuritis with bulbar symptoms mimicking bulbar stroke, requiring percutaneous endoscopic gastrostomy feeds, with significant clinical and radiological recovery over 1 year.

28 August 2015 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
SBSneha Bharadwaj
Sneha Bharadwaj
MLMelissa Lee
Melissa Lee
AMAndrew Campbell Moffat
Andrew Campbell Moffat
A 61-year-old man presented to a country clinic with involuntary orofacial movements and progressive cognitive decline, causing significant disability and psychosocial distress. Review of records uncovered a 7-year history of presentations to several specialties, including memory clinics, neurology, internal medicine and emergency departments, with varied symptoms, extensive complex work up and inconclusive diagnosis. Comprehensive review at our hospital highlighted inconsistent neurological signs, fluctuating cognition and psychosocial stressors, which preceded symptom onset, leading to the diagnosis of a functional movement disorder (FMD), which subsequently improved with relaxation therapy, cognitive–behavioural therapy and physiotherapy. We illustrate a variety of somatic symptoms, diagnostic clues and management outcomes for FMDs, and the importance of diagnostic criteria to minimise costly, time-consuming and ultimately unnecessary tests of exclusion.

29 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SMStephen Robert Macfarlane
Stephen Robert Macfarlane
TGTimo Grimmer
Timo Grimmer
KTKen Teo
Ken Teo
TOTerence J O’brien
Terence J O’brien
MWMichael Woodward
Michael Woodward
MSMarwan Noel Sabbagh
Marwan Noel Sabbagh
IMPORTANCE There are no approved oral disease-modifying treatments for Alzheimer’s disease (AD) with the ability to prolong time in a stable disease state and with clinically meaningful outcomes clear to patients and caregivers. DESIGN The Phase IIb/III ANAVEX2-73-AD-004 study was a randomized, double-blind, placebo-controlled, 48-week trial with prespecified gene or GWAS identified genetic variant populations related to the mechanism of the pharmacological intervention. OBJECTIVE Providing evidence of improved Precision Medicine neurology clinical treatment responses with optimal blarcamesine dose for up to ∼70% of AD patients within prespecified SIGMAR1 (ABCLEAR1) and GWAS identified COL24A1 (ABCLEAR2) and SIGMAR1/COL24A1 (ABCLEAR3) non-missense gene populations. Describing once-daily, oral therapeutic intervention of blarcamesine in early AD, with a differentiated upstream and constitutional mechanism of action by enhancing autophagy through SIGMAR1 activation and restoration of cellular homeostasis. SETTING Multicenter - 52 medical research centers/hospitals in 5 countries. INTERVENTION 508 participants with Early AD (Stage 3) were randomized to receive blarcamesine (n = 338) oral capsules once daily either in medium dose group (30 mg) or in high dose group (50 mg) or placebo (n = 170) for 48 weeks. An open-label-extension study ATTENTION-AD, continued for up to 192 weeks. MAIN OUTCOME AND MEASURES Further improved clinical and biomarker outcomes of the ABCLEAR2 and ABCLEAR3 populations were accretive to the previously reported intent-to-treat (ITT) and prespecified ABCLEAR1 populations. The co-primary cognitive and functional outcomes were assessed as changes in ADAS-Cog13 and ADCS-ADL from baseline to 48 weeks. The outcomes include the secondary outcome CDR-SB as well as patient assessed clinical outcomes CGI-I, NPI-Q and QoL-AD (Quality of Life AD Patient) as well as biomarkers global brain volume changes measured by MRI. All clinical endpoints were analyzed using mixed model for repeated measures (MMRM), and volumetric MRI scans were analyzed by general linear model. RESULTS The ITT population (mean age, 73.7 years; 225 [48.7%] women), consisted of 462 randomized participants, with ABCLEAR1 population comprising of 300 participants, ABCLEAR2 population of 336 participants and ABCLEAR3 of 222 participants. In both the ABCLEAR2 and ABCLEAR3 populations, the co-primary outcomes as well as all other clinical outcomes were statistically significant. ABCLEAR3 blarcamesine group vs. placebo at Week 48 (ADAS-Cog13 difference of −4.179 [95% CI −6.512, −1.845]; P=0.0005; ADCS-ADL difference of +3.131 [95%CI 0.720, 5.542]; P=0.0111; CDR-SB difference of −1.076 [95% CI −1.645, −0.508]; P=0.0002; QoL-AD Patient improvement from baseline of 0.334 [95% CI −1.164, 1.833] and difference of 1.848 [95% CI 0.455, 3.241]; P=0.0095). The clinical outcomes were strongest in the blarcamesine 30 mg cohort (ADAS-Cog13 difference of −4.739 [95% CI −7.370, −2.108]; P=0.0004; ADCS-ADL difference of +4.245 [95%CI 1.518, 6.972]; P=0.0024; CDR-SB difference of −1.414 [95% CI −2.054, −0.775]; P<0.0001; QoL-AD Patient improvement from baseline of 0.182 [95% CI −1.472, 1.835]; and difference of 1.651 [95% CI 0.455, 3.241]; P=0.0392). Whole brain volume loss in blarcamesine group vs. placebo was significantly further decreased from ITT population (37.6%, P=0.0019) to ABCLEAR3 population (44.5%, P=0.0019). Participants in the 30 mg group ABCLEAR3 full safety population with ≥1 serious treatment-emergent adverse events (TEAEs) occurred in 10 participants (12.7%) in the blarcamesine and 6 (9.1%) in the placebo group. Common TEAEs included dizziness, which was transient and mostly mild to moderate in severity. There were no deaths in the blarcamesine group and 1 in the placebo group. CONCLUSIONS AND RELEVANCE Blarcamesine group demonstrated a balanced safety profile with no associated neuroimaging adverse events. The respective once-daily oral 30 mg blarcamesine cohort in the respective ABCLEAR1, ABCLEAR2, and ABCLEAR3 populations demonstrates further improvement of the already adequate safety profile of the ITT population and hence representing the dose with the most balanced benefit-to-risk ratio. In both ABCLEAR2 and ABCLEAR3 populations significant slowing in decline and even stabilization of clinical worsening was demonstrated. Blarcamesine group vs. placebo was 75.9% reduction in decline at 48 weeks in the total blarcamesine group and was 84.7% in the 30 mg dose group, respectively on the prespecified co-primary cognitive endpoint ADAS-Cog13 in the ABCLEAR3 population. Blarcamesine demonstrated consistently significantly improved clinical effect for all clinical endpoints, which was in accordance with significant and further reduced brain atrophy. Furthermore, a significant absolute improvement in Quality of Life (QoL-AD) scores indicating a reversal of negative trajectory for Alzheimer’s disease patients from baseline to end of trial was observed. The Phase IIb/III ANAVEX2-73-AD-004 clinical study confirmed blarcamesine’s consistent efficacy leading to improved cognitive stabilization with continued benefit in the open-label-extension study ATTENTION-AD up to 192 weeks. Evidenced by the Precision Medicine paradigm, including in a prespecified ABCLEAR1 population, a consistent significant improvement for all clinical endpoints in the ABCLEAR2 and ABCLEAR3 populations, respectively, was demonstrated. Coupled with a convenient once daily, oral pill administration, blarcamesine could represent a novel treatment option for up to ∼70% of early AD patients benefiting from further improved outcomes using directed Precision Medicine to alleviate significant medical and economic burden. TRIAL REGISTRATION Clinicaltrials.gov: NCT03790709; Open-label extension NCT04314934 FUNDING This work was funded by Anavex Life Sciences. Key Message Within a heterogeneous Alzheimer’s disease (AD) population, clinical utility of disease-modifying drug candidates could be enhanced via a Precision Medicine approach of treating those with target-relevant genetic profiles, excluding missense gene populations. This effective targeting could alleviate significant medical and economic burden.

Verified
Journal Article
Open access
PDF file
CICharles Inderjeeth
Charles Inderjeeth
DIDiren Che Inderjeeth
Diren Che Inderjeeth
SBSneha Bharadwaj
Sneha Bharadwaj
DKDani Kostova
Dani Kostova
ATAmanda Tillman
Amanda Tillman
MIMaxine Isbel
Maxine Isbel
Objectives: Dementia and osteoporosis are common and debilitating conditions that often coexist in older adults. We investigated mortality in patients with and without dementia as the primary outcome in a prospective memory clinic cohort. Falls and fractures were assessed as secondary outcomes, and associations with baseline acetylcholinesterase inhibitor (AChEI) use were explored. Methods: In a prospective observational cohort study, data were collected during routine clinical visits over four years. Data included demographics, dementia diagnosis, AChEI use, falls, fractures, bone mineral density (BMD) when clinically available, and mortality. Analysis included chi-square tests, Kaplan–Meier survival curves, Cox proportional hazards models, and recurrent-event models. Because AChEI analyses were exploratory and included several related endpoints, Benjamini–Hochberg false discovery rate (FDR) correction was applied to endpoint-level AChEI p-values. Results: 744 patients were enrolled; the mean age was 80.99 ± 6.8 years; 58.5% female; 55.8% with dementia. AChEI use was recorded in 113 patients (15.2%) at baseline. Over 4 years, 16.61% of participants experienced at least one fall with a cumulative fracture risk of 30.90%. Mortality was significantly higher in dementia patients (44.58% vs. 27.05%; p < 0.001). Dementia patients had double the mortality risk (OR: 1.956; 95% CI: 1.425–2.686). Annual and cumulative mortality rates increased progressively from 5.51% and in year 1 to 17.69% and 36.83% respectively by year 4. Baseline AChEI use was not significantly associated with mortality. Risk/100 for patient with dementia vs. without dementia for falls was 4.04 vs. 4.32 and fracture was 4.37 vs. 3.01. AChEI users had a trend of lower incidence/100 patient-years for falls of 3.01 vs. 4.37 and fractures 6.78 vs. 10.09. Conclusions: Dementia patients have higher mortality risk but not falls or fracture risk in this cohort. Although clinical cohort and animal studies suggest a benefit for AChEIs, this was not evident in this study possibly due to clinical cohort limitations. The trend of reduced falls and fracture in the AChEI cohort warrants further study.